Veracyte, Inc. (NASDAQ: VCYT) is a Healthcare company (Medical - Diagnostics & Research) with a market capitalization of $1.9B. The Maz Rating grades it against the other companies in its sector.
About three months ago (July 2, 2026), Veracyte, Inc. had a Maz Rating of 4.97 out of 5 (A, Strong Buy), ranked against the other companies in its sector. Its strongest factor then was Financial Health (4.94), among the strongest in its sector; its weakest was Valuation (1.59), more expensive than most of its sector. The other factors: Growth 4.81 (among the strongest in its sector); Profitability 4.74 (among the strongest in its sector); Momentum 4.58 (among the strongest in its sector). The current rating is for members: log in to see it.
At $24.06, Veracyte, Inc. trades at 15.2x trailing earnings, 3.3x sales and 1.4x book value, with an EV/EBITDA of 13.6. Over the last twelve months it generated about $580M of revenue and $127M of net income. It runs a gross margin of 72.3%, an operating margin of 15.4% and a net margin of 21.8%. It shows return on equity of 9.3%, return on invested capital of 6.0% and a free cash flow yield of 8.2%. On the balance sheet: a debt-to-equity ratio of 0.03 and a current ratio of 5.56. Over the past 52 weeks the share price ranged from $21.91 to $60.91, with a beta of 1.96.
Veracyte, Inc. does not currently pay a dividend.
22 Wall Street analyst ratings cover the stock: 14 Buy, 7 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.